Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

Clinical trial NCT01732861 · COMPLETED

Trial details

NCT number: NCT01732861
Sponsor: Celgene
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Leukemia Lymphocytic Chronic B-Cell

Start date: 2012-12-28
Primary completion: 2019-01-23
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.